Cancer, Positron Emission Tomography, Stimulator of Interferon Gene
Conditions
Brief summary
Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.
Interventions
DRUG[68Ga]Ga-Sa-DABI-4
Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Sponsors
First Affiliated Hospital of Chongqing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously malignant disease.
Exclusion criteria
1. Patients with non-malignant disease. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to \[68Ga\]Ga-Sa-DABI-4 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic efficacy | 15 days | The sensitivity, specificity, and accuracy of \[68Ga\]Ga-Sa-DABI-4 PET |
Countries
China
Contacts
Primary ContactXiaoyang Zhang, PhD
Outcome results
None listed